Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 5/20 | 0.40 |
| ▸ | GRPR | P30550 | 2/20 | 0.38 |
| ▸ | TERT | O14746 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | YWHAZ | P63104 | 1/20 | 0.36 |
| ▸ | NAA50 | Q9GZZ1 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.34 |
| ▸ | OXTR | P30559 | 1/20 | 0.34 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.34 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32678599 | 0.93 | KEAP1 (0.42) | KEAP1GRPRTERTEGFRYWHAZ | |
| SCHEMBL32678598 | 0.93 | KEAP1 (0.42) | KEAP1GRPRTERTEGFRYWHAZ | |
| SCHEMBL29485647 | 0.89 | KEAP1 (0.43) | KEAP1GRPRTERTYWHAZNAA50 | |
| SCHEMBL22922838 | 0.89 | MAPK8 (0.43) | KEAP1NAA50MAPK8MAPK9MAPK10 | |
| SCHEMBL22922802 | 0.88 | NAA50 (0.42) | KEAP1GRPRNAA50MAPK8MAPK9 | |
| SCHEMBL29421977 | 0.88 | KEAP1 (0.44) | KEAP1GRPRTERTYWHAZMAPK8 | |
| SCHEMBL22019122 | 0.87 | TERT (0.40) | KEAP1GRPRTERTCALCRL | |
| SCHEMBL22018478 | 0.87 | TERT (0.41) | KEAP1TERTAVPR2OXTRAVPR1A | |
| SCHEMBL29421961 | 0.87 | KEAP1 (0.44) | KEAP1GRPRTERTYWHAZMAPK8 | |
| SCHEMBL31320748 | 0.86 | EGFR (0.40) | KEAP1GRPRTERTEGFRYWHAZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210024577-A1 | NOVEL PEPTIDE AND PHARMACEUTICAL COMPOSITION FOR TREATING AN EYE DISEASE COMPRISING THE SAME AS AN ACTIVE PHARMACEUTICAL INGREDIENT | YUYU PHARMA, INC. (KR) | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024577-A1 | NOVEL PEPTIDE AND PHARMACEUTICAL COMPOSITION FOR TREATING AN EYE DISEASE COMPRISING THE SAME AS AN ACTIVE PHARMACEUTICAL INGREDIENT | VIP, NGLY1, PROKR1 | KEAP1 1799/4885GRPR 129/4885TERT 4137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.